logo-loader
viewNeuroRx

NeuroRx aims to tackle suicide by treating bipolar depression with new therapy

NeuroRx Inc CEO Dr. Jonathan Javitt tells Proactive Investors the privately-held clinical stage biopharma company is focused on preventing suicide by treating bipolar depression with its small molecule oral drug called NRX-101.

Dr. Javitt says NRX-101 was recently granted Breakthrough Therapy Designation by the FDA for this indication, and is now entering Phase 3 clinical studies with the drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ximen Mining plans to get crews safely back to work at...

Ximen Mining (CVE: XIM- OTC: XXMMF) President and CEO Christopher Anderson joined Steve Darling from Proactive Vancouver to share news the company is planning to send workers back to the Greenwood Mining camp in June. Anderson saying they are putting new protocols in place to protect those...

2 hours, 9 minutes ago

2 min read